---
title: "Apimeds Names Sungjoon Chae Co-Chief Executive Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285242381.md"
description: "Apimeds Pharmaceuticals US, Inc. has appointed Sungjoon Chae as Co-Chief Executive Officer, effective May 4, 2026. This decision follows a stockholder nomination, with no related-party relationships involved. Chae's background in real estate development suggests a focus on complex project management within the pharmaceutical sector. The announcement emphasizes the leadership change rather than detailing the company's drug portfolio or commercial strategy. Apimeds currently has a market cap of $23.64M and an average trading volume of 172,242."
datetime: "2026-05-05T16:58:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285242381.md)
  - [en](https://longbridge.com/en/news/285242381.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285242381.md)
generator: "portal-rs"
---

# Apimeds Names Sungjoon Chae Co-Chief Executive Officer

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has shared an announcement.

On May 4, 2026, Apimeds Pharmaceuticals US, Inc. appointed architect and urban designer Sungjoon Chae as Co-Chief Executive Officer following a nomination by a stockholder, noting there are no related-party relationships or prior arrangements tied to his selection and that his compensation terms are still being finalized. Chae’s extensive background in large-scale real estate development, urban regeneration, and multidisciplinary project leadership underscores an unconventional choice for a pharmaceutical company, suggesting Apimeds may be prioritizing execution-oriented, complex project management capabilities at the top of its corporate structure.

**More about Apimeds Pharmaceuticals US, Inc.**

Apimeds Pharmaceuticals US, Inc. operates in the pharmaceuticals sector, though the company’s core products, therapeutic focus, and target markets are not described in the announcement. The filing primarily highlights a leadership change rather than detailing Apimeds’ drug portfolio, research pipeline, or specific commercial strategy within the healthcare industry.

**Average Trading Volume:** 172,242

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $23.64M

### Related Stocks

- [APUS.US](https://longbridge.com/en/quote/APUS.US.md)

## Related News & Research

- [Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting](https://longbridge.com/en/news/296409897.md)
- [Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug](https://longbridge.com/en/news/296500759.md)
- [GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD](https://longbridge.com/en/news/296084900.md)
- [Diamond Hill Capital Management LLC Investment Advisor Purchases New Position in Aurinia Pharmaceuticals Inc $AUPH](https://longbridge.com/en/news/296195979.md)
- [Madrigal Pharma director John C. Reed files initial beneficial ownership statement](https://longbridge.com/en/news/296270622.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**